Demo Sign up Log In

AstraZeneca PLC Ordinary Shares (AZN)

R&D Expenses

$4.05B

Quarterly · Period ending: Jun 30, 2026 · USD

AZN R&D Expenses

Latest reported$4.05Bperiod endingJun 30, 2026

Latest reported$4.05Bperiod endingJun 30, 2026

AZN Quarterly R&D Expenses ($0.00 → $4.05B)

Quarterly R&D Expenses

High-resolution chart · PNG

AZN r&d expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

AstraZeneca PLC Ordinary Shares R&D Expenses — Quarterly (USD)
Period ending	R&D Expenses (USD)
Jun 30, 2001	669,000,000
Mar 31, 2001	669,822,381
Dec 31, 2000	1,055,978,700
Sep 30, 2000	628,475,518
Jun 30, 2000	613,926,015
Mar 31, 2000	596,230,829
Dec 31, 1999	945,562,378
Sep 30, 1999	664,000,000
Jun 30, 1999	656,000,000
Mar 31, 1999	0
Dec 31, 1998	0
Sep 30, 1998	0
Jun 30, 1998	556,500,000
Mar 31, 1998	0
Dec 31, 1997	0
Sep 30, 1997	0
Jun 30, 1997	0
Mar 31, 1997	0
Dec 31, 1996	0
Sep 30, 1996	0
Jun 30, 1996	0
Mar 31, 1996	0
Dec 31, 1995	0
Sep 30, 1995	0
Jun 30, 1995	0
Mar 31, 1995	0
Dec 31, 1994	0
Sep 30, 1994	0
Jun 30, 1994	0
Mar 31, 1994	0
Dec 31, 1993	0
Sep 30, 1993	0
Jun 30, 1993	0
Mar 31, 1993	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.